Humanwell Healthcare (Group) Co (SHSE:600079) Short-Term Debt: ¥6,109 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600079 Humanwell Healthcare (Group) Co Ltd SHSE:600079
60 GF Score
Price ¥17.93
GF Value ¥21.85
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Humanwell Healthcare (Group) Co Short-Term Debt?

Humanwell Healthcare (Group) Co SHSE:600079 -0.06% 60 Short-Term Debt is ¥6,109 Mil as of Mar. 2026. GuruFocus rates SHSE:600079 with a GF Score™ of 60/100 and a GF Value™ of ¥21.85 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Humanwell Healthcare (Group) Co's Short-Term Debt for the quarter that ended in Mar. 2026 was ¥6,109 Mil.

Humanwell Healthcare (Group) Co's quarterly Short-Term Debt declined from Sep. 2025 (¥6,710 Mil) to Dec. 2025 (¥6,047 Mil) but then increased from Dec. 2025 (¥6,047 Mil) to Mar. 2026 (¥6,109 Mil).

Humanwell Healthcare (Group) Co's annual Short-Term Debt increased from Dec. 2023 (¥6,713 Mil) to Dec. 2024 (¥7,150 Mil) but then declined from Dec. 2024 (¥7,150 Mil) to Dec. 2025 (¥6,047 Mil).

Humanwell Healthcare (Group) Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Humanwell Healthcare (Group) Co Short-Term Debt Related Terms

Humanwell Healthcare (Group) Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Humanwell Healthcare (Group) Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Humanwell Healthcare (Group) Co Short-Term Debt Chart

Humanwell Healthcare (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,898.64 6,588.81 6,713.00 7,149.57 6,046.94

Humanwell Healthcare (Group) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,956.63 7,624.16 6,710.23 6,046.94 6,109.01
SHSE:600079
60GF Score
Humanwell Healthcare (Group) Co Ltd SHSE:600079
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥6,109 Mil mean?
Humanwell Healthcare (Group) Co (SHSE:600079) has a Short-Term Debt of ¥6,109 Mil as of Mar. 2026.
Is Humanwell Healthcare (Group) Co's Short-Term Debt too high?
Humanwell Healthcare (Group) Co's current Short-Term Debt is ¥6,109 Mil. Overall, Humanwell Healthcare (Group) Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Humanwell Healthcare (Group) Co's Short-Term Debt compare to ZTS?
Humanwell Healthcare (Group) Co's Short-Term Debt of ¥6,109 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Humanwell Healthcare (Group) Co's current Short-Term Debt is ¥6,109 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humanwell Healthcare (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co (SHSE:600079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.85, compared to a current price of ¥17.93 — trading 17.9% below its estimated fair value. The current Short-Term Debt is ¥6,109 Mil. Humanwell Healthcare (Group) Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Humanwell Healthcare (Group) Co (SHSE:600079), the current Short-Term Debt is ¥6,109 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Humanwell Healthcare (Group) Co (SHSE:600079) Overvalued in 2026?

Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co stock appears to be undervalued. The current stock price of ¥17.93 is trading 17.9% below its estimated GF Value™ of ¥21.85. GuruFocus considers Humanwell Healthcare (Group) Co to be Modestly Undervalued.

Key valuation signals for SHSE:600079:

  • Short-Term Debt: ¥6,109 Mil
  • GF Value™: ¥21.85 vs. price of ¥17.93 (17.9% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Humanwell Healthcare (Group) Co Business Description

Address No. 666, Gaoxin Avenue, East Lake High-tech Development Zone, Hubei Province, Wuhan, CHN, 430075
Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.
60GF Score

Get the complete analysis for SHSE:600079

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥17.93
Price
¥21.85
GF Value